Physician profile
Farhad Anoosh
NPI 1558501668
$3,798.15
in general payments reported to CMS, 2019-2025
28 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $257 · 2021: $313 · 2022: $506 · 2023: $365 · 2024: $770 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,016.42 | 2019 | |
| Davol INC. | $537.87 | 2021-2025 | Phasix Mesh |
| Intuitive Surgical, INC. | $478.97 | 2019-2023 | Da Vinci Surgical System |
| Ethicon US, LLC | $285.64 | 2019-2025 | Enseal, Echelon Circular |
| Boston Scientific Corporation | $202.94 | 2021-2024 | Spyglass Discover, Apollo Esg System |
| W. L. Gore & Associates, INC. | $187.94 | 2021-2024 | Gore Synecor Biomaterial |
| Baxter Healthcare | $174.56 | 2019-2023 | Tisseel |
| Cumberland Pharmaceuticals, INC. | $112.14 | 2020-2025 | Caldolor |
| Lilly USA, LLC | $104.67 | 2024-2025 | Zepbound |
| Acell, INC. | $77.82 | 2019 | |
| Novo Nordisk INC | $76.39 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.56 | 2022-2024 | Gattex |
| Stryker Corporation | $59.14 | 2022 | |
| Teleflex LLC | $52.55 | 2019-2021 | |
| Redhill Biopharma INC. | $43.77 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $39.18 | 2024 | |
| Medtronic, INC. | $33.73 | 2022-2023 | Signia |
| Intra-Sana Laboratories | $33.48 | 2022 | |
| Tela Bio, INC. | $33.36 | 2020-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Kowa Pharmaceuticals America, INC. | $30.56 | 2022 | |
| Vivus LLC | $29.98 | 2020-2021 | |
| Integra Lifesciences Corporation | $21.71 | 2023 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Kci USA, INC. | $20.34 | 2023 | V.A.C. Veraflo, Prevena |
| Avanos Medical | $18.97 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $17.65 | 2019 | |
| Endo Pharmaceuticals INC. | $16.29 | 2019 | |
| Bard Access Systems, INC. | $16.29 | 2019 | |
| Axonics, INC. | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Anoosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.